Anthony T. Reder to Multiple Sclerosis, Relapsing-Remitting
This is a "connection" page, showing publications Anthony T. Reder has written about Multiple Sclerosis, Relapsing-Remitting.
Connection Strength
6.242
-
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024 04 15; 389:578328.
Score: 0.899
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
Score: 0.735
-
Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring. Neurology. 2019 04 09; 92(15):696-697.
Score: 0.638
-
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. CNS Drugs. 2016 Feb; 30(2):135-47.
Score: 0.513
-
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
Score: 0.347
-
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
Score: 0.302
-
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008 May; 28(5):317-31.
Score: 0.300
-
Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007 May; 13(4):459-70.
Score: 0.275
-
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
Score: 0.213
-
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
Score: 0.188
-
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
Score: 0.183
-
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
Score: 0.150
-
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
Score: 0.140
-
Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep; 9:158-62.
Score: 0.133
-
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15(1):35-46.
Score: 0.127
-
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep; 3(5):629-38.
Score: 0.115
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
Score: 0.113
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
Score: 0.106
-
Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
Score: 0.102
-
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
Score: 0.098
-
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
Score: 0.095
-
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb; 11(2):165-83.
Score: 0.090
-
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
Score: 0.084
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.084
-
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
Score: 0.082
-
IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 Mar; 195(1-2):116-20.
Score: 0.074
-
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
Score: 0.056